Novel coronavirus infection COVID-19: extrapulmonary manifestations

Cover Page

Cite item

Full Text

Abstract

The novel coronavirus infection COVID-19 in most cases manifests with respiratory symptoms and fever, however, some patients may have cardiovascular and gastroenterological manifestations. A feature of the clinical syndrome of COVID-19 is the development of pronounced immunopathological reactions and disorders of hemostasis, leading to the development of a wide range of cardiovascular complications. The course of COVID-19 may be complicated by the development of acute myocardial infarction, venous and arterial thrombosis and thromboembolism in various vascular pools, the development of acute myocardial damage and myocarditis. Among the gastroenterological manifestations, diarrhea, nausea or vomiting, as well as abdominal pain, are most often detected. These symptoms may precede the appearance of respiratory signs of the disease, and in some cases come to the fore in the clinical picture of the disease. In addition, in some patients there are laboratory signs of liver injury (increased serum transaminases). The exact pathogenesis of the above disorders continues to be studied.

About the authors

I. V. Maev

Yevdokimov Moscow State University of Medicine and Dentistry

Email: dna-mit8@mail.ru
ORCID iD: 0000-0001-6114-564X

акад. РАН, д-р мед. наук, проф., зав. каф. пропедевтики внутренних болезней и гастроэнтерологии, заслуженный врач РФ, заслуженный деятель науки РФ

Russian Federation, Moscow

A. V. Shpektor

Yevdokimov Moscow State University of Medicine and Dentistry

Email: dna-mit8@mail.ru
ORCID iD: 0000-0001-6190-6808

чл.-кор. РАН, д-р мед. наук, проф., зав. каф. кардиологии, заслуженный врач РФ

Russian Federation, Moscow

E. Yu. Vasilyeva

Yevdokimov Moscow State University of Medicine and Dentistry

Email: dna-mit8@mail.ru
ORCID iD: 0000-0002-6310-7636

д-р мед. наук, проф., зав. лаб. атеротромбоза, заслуженный врач РФ. 

Russian Federation, Moscow

V. N. Manchurov

Yevdokimov Moscow State University of Medicine and Dentistry

Email: dna-mit8@mail.ru
ORCID iD: 0000-0003-4322-8243

канд. мед. наук, доц. каф. кардиологии

Russian Federation, Moscow

D. N. Andreev

Yevdokimov Moscow State University of Medicine and Dentistry

Author for correspondence.
Email: dna-mit8@mail.ru
ORCID iD: 0000-0002-4007-7112

канд. мед. наук, доц. каф. пропедевтики внутренних болезней и гастроэнтерологии

Russian Federation, Moscow

References

  1. Zhu N, Zhang D, Wang W, et al.; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-33. doi: 10.1056/NEJMoa2001017
  2. Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. J Chin Med Assoc. 2020 Mar;83(3):217-20. doi: 10.1097/JCMA.0000000000000270
  3. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020 May;109:102433. doi: 10.1016/j.jaut.2020.102433
  4. Guan WJ, Ni ZY, Hu Y, et al.; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-20. doi: 10.1056/NEJMoa2002032
  5. Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020 May 5;172(9):577-82. doi: 10.7326/M20-0504. PMID: 32150748
  6. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Feb 24. doi: 10.1001/jama.2020.2648. PMID: 32091533.
  7. Вступительное слово Генерального директора на пресс-брифинге по COVID-19 11 марта 2020 г. [Opening address by the Director-General at a COVID-19 press briefing on March 11, 2020. Published online at WHO.int. (In Russ.)]. https://www.who.int/ru/dg/speeches/detail/ who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
  8. Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. Coronavirus Pandemic (COVID-19). Published online at OurWorldInData.org. https://ourworldindata.org/coronavirus
  9. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020 Mar-Apr;34:101623. doi: 10.1016/j.tmaid.2020.101623
  10. Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020 Apr 28:1-12. doi: 10.1038/s41577-020-0311-8
  11. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;e201017. doi: 10.1001/jamacardio.2020.1017
  12. Bikdeli B, Madhavan M, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol. 2020 Apr 17. doi: 10.1016/j.jacc.2020.04.031
  13. Kochi AN, Tagliari AP, Forleo GB, et al. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. 2020;10.1111/jce.14479. doi: 10.1111/jce.14479
  14. Kollias A, Kyriakoulis KG, Dimakakos E, et al. Thromboembolic Risk and Anticoagulant Therapy in COVID-19 Patients: Emerging Evidence and Call for Action. Br J Haematol. 2020 Apr 18. doi: 10.1111/bjh.16727
  15. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of Thrombotic Complications in Critically Ill ICU Patients With COVID-19. Thromb Res. 2020 Apr 10;S0049-3848(20)30120-1. doi: 10.1016/j.thromres.2020.04.013
  16. Akhmerov A, Marban E. COVID-19 and the Heart. Circ Res. 2020;10.1161/CIRCRESAHA.120.317055. doi: 10.1161/CIRCRESAHA.120.317055
  17. Chapman AR, Bularga A, Mills NL. High-Sensitivity Cardiac Troponin Can Be An Ally in the Fight Against COVID-19. Circulation. 2020;10.1161/CIRCULATIONAHA.120.047008. doi: 10.1161/CIRCULATIONAHA.120.047008
  18. Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis. J Thromb Haemost. 2020 Apr 17. doi: 10.1111/jth.14850
  19. Zhai Z, Li C, Chen Y, et al. Prevention and Treatment of Venous Thromboembolism Associated With Coronavirus Disease 2019 Infection: A Consensus Statement Before Guidelines. Thromb Haemost. 2020 Apr 21. doi: 10.1055/s-0040-1710019
  20. Tang N, Bai H, Chen X, et al. Anticoagulant Treatment Is Associated With Decreased Mortality in Severe Coronavirus Disease 2019 Patients With Coagulopathy. J Thromb Haemost. 2020 May;18(5):1094-9. doi: 10.1111/jth.14817
  21. Marone EM, Rinaldi LF. Upsurge of Deep Venous Thrombosis in Patients Affected by COVID-19: Preliminary Data and Possible Explanations. J Vasc Surg Venous Lymphat Disord. 2020 Apr 17;S2213-333X(20)30214-6. doi: 10.1016/j.jvsv.2020.04.004
  22. Lodigiani C, Iapichino G, Carenzo L, et al.; Humanitas COVID-19 Task Force. Venous and Arterial Thromboembolic Complications in COVID-19 Patients Admitted to an Academic Hospital in Milan, Italy. Thromb Res. 2020 Apr 23;191:9-14. doi: 10.1016/j.thromres.2020.04.024
  23. Vulliamy P, Jacob S, Davenport RA. Acute Aorto-Iliac and Mesenteric Arterial Thromboses as Presenting Features of COVID-19. Br J Haematol. 2020 Apr 30. doi: 10.1111/bjh.16760
  24. Le Berre A, Marteau V, Emmerich J, Zins M. Concomitant Acute Aortic Thrombosis and Pulmonary Embolism Complicating COVID-19 Pneumonia. Diagn Interv Imaging. 2020 Apr 16;101(5):321-2. doi: 10.1016/j.diii.2020.04.003
  25. Casini A, Alberio L, Angelillo-Scherrer A, et al. Thromboprophylaxis and Laboratory Monitoring for In-Hospital Patients With COVID-19 – A Swiss Consensus Statement by the Working Party Hemostasis. Swiss Med Wkly. 2020 Apr 11;150:w20247. doi: 10.4414/smw.2020.20247
  26. Bangalore S, Sharma A, Slotwiner A, et al. ST-Segment Elevation in Patients with Covid-19 – A Case Series. N Engl J Med. 2020 Apr 17: NEJMc2009020. doi: 10.1056/NEJMc2009020
  27. Никитская Е.А., Марюхнич Е.В., Саввинова П.П. и др. Вирусы герпеса человека и атеросклероз. Современный взгляд. Креативная кардиология. 2015;9(2):54-62 [Nikitskaya EA, Maryukhnich EV, Savvinova PP, et al. Human herpes viruses and atherosclerosis. Modern look. Creative cardiology. 2015;9(2):54-62 (In Russ.)]. doi: 10.15275/kreatkard.2015.02.05
  28. Nikitskaya EA, Grivel JC, Maryukhnich EV, et al. Cytomegalovirus in Plasma of Acute Coronary Syndrome Patients. Acta Naturae. 2016 Apr-Jun;8(2):102-7.
  29. Nikitskaya E, Lebedeva A, Ivanova O, et al. Cytomegalovirus-Productive Infection Is Associated With Acute Coronary Syndrome. J Am Heart Assoc. 2016 Aug 20;5(8):e003759. doi: 10.1161/JAHA.116.003759
  30. Воробьева И.И., Рыжкова Е.В., Васильева Е.Ю., Шпектор А.В. Влияние системного воспаления на эффект антиагрегантной терапии у больных с острым коронарным синдромом. Креативная кардиология, 2012;1:5-14 [Vorobyeva II, Ryzhkova EV, Vasilieva EYu, Spector AV. The effect of systemic inflammation on the effect of antiplatelet therapy in patients with acute coronary syndrome. Creative Cardiology. 2012;1:5-14 (In Russ.)].
  31. Du Y, Tu L, Zhu P, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study. Am J Respir Crit Care Med. 2020;10.1164/rccm.202003-0543OC. doi: 10.1164/rccm.202003-0543OC
  32. Mahmud E, Dauerman HL, Welt FG, et al. Management of Acute Myocardial Infarction During the COVID-19 Pandemic. Catheter Cardiovasc Interv. 2020 Apr 20.
  33. Jing ZC, Zhu HD, Yan XW, et al.; on behalf of the COVID-19 & AMI committee of Peking Union Medical College Hospital, Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak. Eur Heat J. doi: 10.1093/eurheartj/ehaa258
  34. Doyen D, Moceri P, Ducreux D, Dellamonica J. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. Lancet. 2020 Apr 23. doi: 10.1016/S0140-6736(20)30912-0
  35. Zeng JH, Liu YX, Yuan J, et al. First Case of COVID-19 Complicated With Fulminant Myocarditis: A Case Report and Insights. Infection. 2020 Apr 10. doi: 10.1007/s15010-020-01424-5
  36. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. Last updated on 21 April 2020. Accessed May 10, 2020. https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance
  37. Courand P-Y, Harbaoui B, Bonnet M, Lantelme P. Spontaneous Coronary Artery Dissection in a Patient with COVID-19. JACC: Cardiovascular Interventions. 2020. doi: 10.1016/j.jcin.2020.04.006
  38. Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020. doi: 10.1111/jth.14830
  39. Thachil J, Tang N, Gando S, et al. ISTH Interim Guidance on Recognition and Management of Coagulopathy in COVID-19. J Thromb Haemost. 2020 May;18(5):1023-26. doi: 10.1111/jth.14810
  40. Thygesen K, Alpert JS, Jaffe AS, et al.; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018 Oct 30;72(18):2231-64. doi: 10.1016/j.jacc.2018.08.1038
  41. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;e201585. doi: 10.1001/jama.2020.1585
  42. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5
  43. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi: 10.1016/S0140-6736(20)30566-3
  44. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020;e200950. doi: 10.1001/jamacardio.2020.0950
  45. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational. Lancet Respir Med. 2020. doi: 10.1016/S2213-2600(20)30079-5
  46. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;1-3. doi: 10.1007/s00134-020-05991-x
  47. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020;ehaa190. doi: 10.1093/eurheartj/ehaa190
  48. Fried JA, Ramasubbu K, Bhatt R, et al. The Variety of Cardiovascular Presentations of COVID-19. Circulation. 2020 Apr 3. doi: 10.1161/CIRCULATIONAHA.120.047164
  49. Kim IC, Kim JY, Kim HA, Han S. COVID-19-related Myocarditis in a 21-year-old Female Patient. Eur Heart J. 2020 Apr 13; ehaa288. doi: 10.1093/eurheartj/ehaa288
  50. Irabien-Ortiz A. Fulminant myocarditis due to COVID-19. Rev Esp Cardiol. 2020 Apr 10. doi: 10.1016/j.recesp.2020.04.001
  51. Varga Z, Flammer AJ, Steiger P, et al. Endothelial Cell Infection and Endotheliitis in COVID-19. Lancet. 2020 Apr 20;395(10234):1417-8. doi: 10.1016/S0140-6736(20)30937-5
  52. Escher R, Breakey N, Lämmle B. Severe COVID-19 Infection Associated With Endothelial Activation. Thromb Res. 2020 Apr 15;190:62. doi: 10.1016/j.thromres.2020.04.014
  53. Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res. 2019;181:77-83. doi: 10.1016/j.thromres.2019.07.013
  54. Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus Modulation of Myocardial ACE2 Expression and Inflammation in Patients With SARS. Eur J Clin Invest. 2009 Jul;39(7):618-25. doi: 10.1111/j.1365-2362.2009.02153.x
  55. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;10.1001/jamacardio.2020.1096. doi: 10.1001/jamacardio.2020.1096
  56. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 Apr;8(4):420-2. doi: 10.1016/S2213-2600(20)30076-X
  57. Fung G, Luo H, Qiu Y, et al. Myocarditis. Circulation Research. 2016;118:496-514. doi: 10.1161/CIRCRESAHA.115.306573
  58. Holshue ML, DeBolt C, Lindquist S, et al.; Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020 Mar 5;382(10):929-36. doi: 10.1056/NEJMoa2001191
  59. WHO issues consensus document on the epidemiology of SARS. Wkly Epidemiol Rec. 2003 Oct 24;78(43):373-5.
  60. Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. J Gastroenterol Hepatol. 2020 May;35(5):744-8. doi: 10.1111/jgh.15047
  61. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020 Feb 19. doi: 10.1111/all.14238. PMID: 32077115.
  62. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-13. doi: 10.1016/S0140-6736(20)30211-7
  63. Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020 May 5;133(9):1025-31. doi: 10.1097/CM9.0000000000000744
  64. Lu X, Zhang L, Du H, et al.; Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 Infection in Children. N Engl J Med. 2020 Apr 23;382(17):1663-5. doi: 10.1056/NEJMc2005073
  65. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020 Apr;20(4):425-34. doi: 10.1016/S1473-3099(20)30086-4
  66. Xiao F, Tang M, Zheng X, et al. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020 May;158(6):1831-3.e3. doi: 10.1053/j.gastro.2020.02.055
  67. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020 Feb 19;368:m606. doi: 10.1136/bmj.m606
  68. Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther. 2020 May;51(9):843-51. doi: 10.1111/apt.15731
  69. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;10.1002/jmv.25757. doi: 10.1002/jmv.25757
  70. Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020 May 12. doi: 10.1016/S2468-1253(20)30126-6
  71. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428-30. doi: 10.1016/S2468-1253(20)30057-1
  72. Xu L, Liu J, Lu M, et al. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020 May;40(5):998-1004. doi: 10.1111/liv.14435
  73. Wang F, Wang H, Fan J, et al. Pancreatic injury patterns in patients with COVID-19 pneumonia. Gastroenterology. 2020 Apr 1. doi: 10.1053/j.gastro.2020.03.055
  74. de-Madaria E, Siau K, Cárdenas-Jaén K. Increased amylase and lipase in patients with COVID-19 pneumonia: don´t blame the pancreas just yet! Gastroenterology. 2020 Apr 21:S0016-5085(20)30561-8. doi: 10.1053/j.gastro.2020.04.044
  75. Hadi A, Werge M, Kristiansen KT, et al. Coronavirus Disease-19 (COVID-19) associated with severe acute pancreatitis: Case report on three family members. Pancreatology. 2020 May 5:S1424-3903(20)30147-2. doi: 10.1016/j.pan.2020.04.021. PMID: 32387082.
  76. Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020 Jun;69(6):1002-9. doi: 10.1136/gutjnl-2020-320926
  77. Pan L, Mu M, Yang P, et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol. 2020 May;115(5):766-73. doi: 10.14309/ajg.0000000000000620
  78. Hung IF, Cheng VC, Wu AK, et al. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis. 2004 Sep;10(9):1550-7. doi: 10.3201/eid1009.040058
  79. Zhou J, Li C, Zhao G, et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Sci Adv. 2017 Nov 15;3(11):eaao4966. doi: 10.1126/sciadv.aao4966
  80. Leung WK, To KF, Chan PK, et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology. 2003 Oct;125(4):1011-7. doi: 10.1016/s0016-5085(03)01215-0
  81. Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020 Mar 27;367(6485):1444-8. doi: 10.1126/science.abb2762
  82. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-80.e8. doi: 10.1016/j.cell.2020.02.052
  83. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020 Mar 13;367(6483):1260-3. doi: 10.1126/science.abb2507
  84. Malik YA. Properties of Coronavirus and SARS-CoV-2. Malays J Pathol. 2020;42(1):3-11.
  85. Lee IC, Huo TI, Huang YH. Gastrointestinal and Liver Manifestations in Patients with COVID-19. J Chin Med Assoc. 2020. doi: 10.1097/JCMA.0000000000000319
  86. Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology. 2020 May;158(6):1518-9. doi: 10.1053/j.gastro.2020.02.054
  87. Chai X, Hu L, Zhang Y, et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. doi: 10.1101/2020.02.03.931766
  88. Banales JM, Huebert RC, Karlsen T, et al. Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol. 2019 May;16(5):269-81. doi: 10.1038/s41575-019-0125-y
  89. Feng G, Zheng KI, Yan QQ, et al. COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. J Clin Transl Hepatol. 2020 Mar 28;8(1):18-24. doi: 10.14218/JCTH.2020.00018
  90. Mukherjee R, Smith A, Sutton R. Covid-19-related pancreatic injury. Br J Surg. 2020 Apr 30. doi: 10.1002/bjs.11645. PMID: 32352160.
  91. Liu F, Long X, Zhang B, et al. ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. Clin Gastroenterol Hepatol. 2020 Apr 22:S1542-3565(20)30537-1.
  92. Patel KP, Patel PA, Vunnam RR, et al. Gastrointestinal, hepatobiliary, and pancreatic manifestations of COVID-19. J Clin Virol. 2020 Apr 29;128:104386. doi: 10.1016/j.jcv.2020.104386.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies